company_name,research_stage,small_molecules,small_molecules_citations,peptides,peptides_citations,proteins,proteins_citations,antibodies,antibodies_citations,antibody_conjugates,antibody_conjugates_citations,fusion_proteins,fusion_proteins_citations,nucleic_acid_therapeutics,nucleic_acid_therapeutics_citations,gene_cell_therapies,gene_cell_therapies_citations,vaccines,vaccines_citations,protein_degraders,protein_degraders_citations,other_modalities,other_modalities_citations
23 century clinic,Clinical (Phase I–III),No,Not found,No,Not found,Yes (interleukin),https://23chealthcare.com/about-us/,Yes (bispecific antibodies),https://23chealthcare.com/about-us/,No,Not found,No,Not found,No,Not found,Yes (CAR-T),"https://23chealthcare.com/about-us/, https://23chealthcare.com/",No,Not found,No,Not found,No,Not found
nexcella inc,Clinical (Phase I–III),No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,Yes (CAR-T),"https://finance.yahoo.com/news/nexcella-immix-biopharma-subsidiary-track-133700657.html, https://www.cgtlive.com/view/immix-nexcella-make-progress-us-trial-light-chain-amyloidosis-car-t-nxc-201, https://immixbio.com/immix-biopharma-subsidiary-nexcella-completes-pre-ind-meeting-with-fda-on-nxc-201-us-clinical-trial/",No,Not found,No,Not found,No,Not found
targazyme inc,Clinical (Phase I–III),Yes (small molecule),https://www.linkedin.com/company/targazyme,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,Yes (gene therapy),"https://www.targazyme.com/, https://www.linkedin.com/company/targazyme",No,Not found,No,Not found,No,Not found
shenzhen pregene biopharma co ltd,Clinical (Phase I–III),No,Not found,No,Not found,No,Not found,Yes (nanobody),http://en.pregene.com/,No,Not found,No,Not found,No,Not found,Yes (CAR-T),"http://en.pregene.com/, https://www.prnewswire.com/news-releases/pregene-enters-into-innovative-partnership-with-cellpoint-to-develop-anti-bcma-car-t-cell-therapy-in-europe-and-the-us-301518944.html",No,Not found,No,Not found,No,Not found
biotherapy services ltd,Clinical (Phase I–III),No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found
carsgen therapeutics ltd,Clinical (Phase I–III),No,Not found,No,Not found,Yes (cytokine),https://www.carsgen.com/,No,Not found,No,Not found,No,Not found,No,Not found,Yes (CAR-T),"https://www.bloomberg.com/profile/company/1186504D:CH, https://www.carsgen.com/, https://www.linkedin.com/company/carsgen-therapeutics, https://www.biospace.com/employer/543068/carsgen-therapeutics",No,Not found,No,Not found,No,Not found
dc prime bv,Preclinical,No,Not found,Yes (peptide),https://www.bionity.com/en/companies/1040181/dcprime-bv.html,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found
abelzeta inc,Preclinical,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,No,Not found,Yes (CAR-T),"https://www.linkedin.com/company/abelzeta, https://synapse.patsnap.com/organization/ec71f92de4c0f0b557150c986c16b7f3, https://www.outsourcedpharma.com/doc/abelzeta-pharma-announces-agreement-with-astrazeneca-to-co-develop-a-novel-glypican-gpc-armored-car-t-therapy-in-china-0001, https://www.prnewswire.com/news-releases/cbmg-holdings-announces-name-change-to-abelzeta-pharma-inc-301993427.html, https://www.prnewswire.com/news-releases/abelzeta-announces-promising-long-term-outcomes-for-c-car039-a-novel-cd19cd20-bi-specific-car-t-therapy-in-patients-with-rr-b-nhl-at-eha-2025-302482119.html",No,Not found,No,Not found,No,Not found
